GNTA Depositi SEC - Genenta Science S.p.A. - Depositary Receipt (Common Stock)- Relazione annuale, dichiarazione di delega, prospetto informativo

Statistiche di base

CIK

880643

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Genenta Science S.p.A. - Depositary Receipt (Common Stock)

SEC Filings (Chronological Order)

Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.

February 14, 2013	SC 13G/A	RA CAPITAL MANAGEMENT, L.P. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Genta Incorporated (Name of Issuer) Common Shares, $0.001 par value (Title of Class of Securities) 37245M801 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
February 14, 2013	SC 13G/A	TANG CAPITAL PARTNERS LP - AMENDMENT NO. 4 SC 13G/A 1 c213134sc13ga4.htm AMENDMENT NO. 4 SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Genta Incorporated (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 37245M801 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of This Statement) Check the appro
February 13, 2013	EX-99.1	JOINT FILING AGREEMENT EX-1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G, dated February 12, 2013, with respect to the shares of Genta Incorporated’s Common Stock, par value $0.
February 13, 2013	SC 13G/A	Boxer Capital, LLC - SC 13G/A SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. 3) Under the Securities Exchange Act of 1934 Genta Incorporated (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37245M603 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p
August 2, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 2, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
July 30, 2012	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 30, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
July 27, 2012	8-K	Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 24, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
July 26, 2012	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 26, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
June 22, 2012	SC 13D	SIEGEL GARY - SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Genta Incorporated (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 37245M801 (CUSIP Number) Gary Siegel Vice President, Finance Genta Incorporated 200 Connell Drive Berkeley Heights, New Jersey 07922 (908) 286-9800 (Name, Address an
June 22, 2012	SC 13D/A	WARRELL RAYMOND P JR - SCHEDULE 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Genta Incorporated (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 37245M801 (CUSIP Number) Raymond P. Warrell, Jr., M.D. Chairman and Chief Executive Officer Genta Incorporated 200 Connell Drive Berkeley Height
June 22, 2012	DEF 14A	- DEFINITIVE PROXY UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for use of the Commissiononly (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statem
June 18, 2012	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 18, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
June 18, 2012	EX-99.1	200 Connell Drive Berkeley Heights, NJ 07922 Genta Announces Agreement with FDA on Special Protocol Assessment of Phase 3 Trial of Tesetaxel as Initial Chemotherapy for Women with Metastatic Breast Cancer -- Proposed trial to compare two oral single EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Announces Agreement with FDA on Special Protocol Assessment of Phase 3 Trial of Tesetaxel as Initial Chemotherapy for Women with Metastatic Breast Cancer - Proposed trial to compare two oral single agents -Agreement secured on progression-free survival as primary endpoint BERKELEY HEIGHTS, NJ – June 1
June 15, 2012	EX-10.2	AMENDMENT AGREEMENT EX-10.2 3 ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 AMENDMENT AGREEMENT This AMENDMENT AGREEMENT (this “Agreement”), dated as of June 14, 2012, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). WHEREAS, the Company has previously issued certain: (a) June 2008 Notes; (b) April 2009 Notes; (c) Jul
June 15, 2012	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
June 15, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Unregistered Sales of Equity Securities - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 13, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
June 15, 2012	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
June 15, 2012	EX-10.1	FIRST AMENDMENT AGREEMENT EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 FIRST AMENDMENT AGREEMENT This FIRST AMENDMENT AGREEMENT (this “Agreement”), dated as of June 14, 2012, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “June Purchaser” and collectively the “June Purchasers”). Capitalized terms used herein and not defined shall have the meanings set
June 15, 2012	EX-10.3	[Signature Pages Follow] EX-10.3 4 ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 June 14, 2012 Genta Incorporated 200 Connell Drive Berkeley Heights, NJ 07922 Attention: Raymond P. Warrell, Jr., M.D. Re: Waiver of Conversion Limits Ladies and Gentlemen: Reference is made to the following debt obligations of Genta, Inc. (the “Company”): 1. The Company’s 6% Senior Secured Convertible Promissory I Notes issued pursuant to that certai
June 8, 2012	PRE 14A	- PRELIMINARY PROXY UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for use of the Commissiononly (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statem
May 31, 2012	EX-99.1	200 Connell Drive Berkeley Heights, NJ 07922 Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Initiates Randomized Trial of Tesetaxel as First-Line Therapy for Women with Recurrent Breast Cancer - “All Oral Chemotherapy” Study Compares Two Different Schedules of Tesetaxel with Capecitabine BERKELEY HEIGHTS, NJ – May 31, 2012 – Genta Incorporated (GNTA) announced today that the first patient has been accrued to a new randomized
May 31, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 31, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 25, 2012	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 25, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 24, 2012	EX-99.1	Genta Announces Results of Tesetaxel Confirmatory Trial in Patients with Advanced Gastric Cancer -- New data for response, survival, and safety to be presented at ASCO -- Results support projections for new randomized trial Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Announces Results of Tesetaxel Confirmatory Trial in Patients with Advanced Gastric Cancer - New data for response, survival, and safety to be presented at ASCO - Results support projections for new randomized trial BERKELEY HEIGHTS, NJ – May 24, 2012 - Genta Incorporated (GNTA) today announced results from the Company’s Phase 2, conf
May 24, 2012	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 24, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 22, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 22, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 22, 2012	EX-99.1	Tesetaxel Results as Initial Chemotherapy for Women with Recurrent Breast Cancer to be Highlighted at ASCO --Promising results for response and progression-free survival --Company to proceed with randomized trial Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Tesetaxel Results as Initial Chemotherapy for Women with Recurrent Breast Cancer to be Highlighted at ASCO -Promising results for response and progression-free survival -Company to proceed with randomized trial BERKELEY HEIGHTS, NJ – May 22, 2012 - Genta Incorporated (GNTA) today announced results from the Company’s Phase 2 clinical trial u
May 14, 2012	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19635 GENTA
May 14, 2012	EX-99.1	200 Connell Drive Berkeley Heights, NJ 07922 Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports First Quarter 2012 Financial Results BERKELEY HEIGHTS, NJ – May 14, 2012 – Genta Incorporated (GNTA) today reported results for the quarter ended March 31, 2012. For the first quarter of 2012, the Company reported net income of $5.2 million, or $0.00 net income per basic and diluted share, compared with net income
May 14, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 14, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 8, 2012	EX-99.1	Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer -- TESEGAST Trial Opens in U.S., EU, and Asia -- Double-Blind Study Uses “All Oral” Chemotherapy Regimen as 2nd-Line Treatment Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer - TESEGAST Trial Opens in U.S., EU, and Asia - Double-Blind Study Uses “All Oral” Chemotherapy Regimen as 2nd-Line Treatment BERKELEY HEIGHTS, NJ – May 8, 2012 – Genta Incorporated (OTCBB: GNTA.OB) announced today that the first patient has been accrued to a new randomized clin
May 8, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 8, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numbe
April 24, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 24, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
April 24, 2012	EX-99.1	200 Connell Drive Berkeley Heights, NJ 07922 Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to its Board of Directors Dr. Daniel Von Hoff to Retire as Director Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to its Board of Directors Dr. Daniel Von Hoff to Retire as Director BERKELEY HEIGHTS, NJ – April 24, 2012 – Genta Incorporated (OTCBB: GNTA.OB) announced today the appointments of Dr. Brian Leyland-Jones and Richard J. Moran, as members of the Company’s Board of Directors. The Comp
April 20, 2012	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 20, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
March 29, 2012	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File Numb
March 29, 2012	EX-10.1	SECURITIES PURCHASE Dated as of March 28, 2012 by and among GENTA INCORPORATED SECURITIES PURCHASE AGREEMENT EX-10.1 3 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT Dated as of March 28, 2012 by and among GENTA INCORPORATED and THE PURCHASERS LISTED ON EXHIBIT A SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) dated as of March 28, 2012 (the “Effective Date”) by and among Genta Incorporated, a Delaware corporation (the “Company”), and each of the pu
March 29, 2012	EX-10.2	AMENDMENT AGREEMENT EX-10.2 4 ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 AMENDMENT AGREEMENT This AMENDMENT AGREEMENT (this “Agreement”), dated as of March 28, 2012 (the “Amendment Date”), is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties whose names are set forth on Exhibit A attached hereto (each a “Holder” and collectively the “Holders”). WHEREAS, the Company ha
March 29, 2012	EX-4.1	GENTA INCORPORATED Form of Senior Secured Convertible Promissory Note due March 30, 2022 I Note No. _____ $___________ EX-4.1 2 ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND SUCH
March 29, 2012	EX-99.1	Genta Completes Financing of Up to $12.0 Million Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Completes Financing of Up to $12.0 Million - Proceeds enable initiation of randomized trials of tesetaxel in both gastric and breast cancer - Transaction eliminates conversion price reset and requirement for reverse stock split BERKELEY HEIGHTS, NJ – March 29, 2012 – Genta Incorporated (OTCBB: GNTA.OB) announced today that the Company
March 29, 2012	EX-10.3	AMENDED AND RESTATED GENERAL SECURITY AGREEMENT Dated as of March 30, 2012 THE GRANTORS REFERRED TO HEREIN as Grantors TANG CAPITAL PARTNERS, L.P. as Agent AMENDED AND RESTATED GENERAL SECURITY AGREEMENT EX-10.3 5 ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 AMENDED AND RESTATED GENERAL SECURITY AGREEMENT Dated as of March 30, 2012 between THE GRANTORS REFERRED TO HEREIN as Grantors and TANG CAPITAL PARTNERS, L.P. as Agent AMENDED AND RESTATED GENERAL SECURITY AGREEMENT Amended and Restated General Security Agreement dated as of March 30, 2012 (the “Agreement”) between Genta Incorporated, a Delaware corpo
March 28, 2012	EX-10.14	GENTA INCORPORATED 2009 STOCK INCENTIVE PLAN (As Amended and Restated September 8, 2011) EX-10.14 2 ex10-14.htm EXHIBIT 10.14 Exhibit 10.14 GENTA INCORPORATED 2009 STOCK INCENTIVE PLAN (As Amended and Restated September 8, 2011) TABLE OF CONTENTS Page ARTICLE I GENERAL 1 1.1 Purpose 1 1.2 Administration 1 1.3 Persons Eligible for Awards 2 1.4 Types of Awards Under Plan 2 1.5 Shares Available for Awards 2 1.6 Definitions of Certain Terms 3 ARTICLE II AWARDS UNDER THE PLAN 5 2.1 Agreeme
March 28, 2012	10-K	Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2011 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 000-19635 GENTA INCORPORATED (Exact
March 28, 2012	EX-21	GENTA INCORPORATED SUBSIDIARIES OF THE REGISTRANT EX-21 3 ex21.htm EXHIBIT 21 Exhibit 21 GENTA INCORPORATED SUBSIDIARIES OF THE REGISTRANT The names of the Company’s subsidiaries are omitted. Such subsidiaries would not, if considered in the aggregate as a single subsidiary, constitute a significant subsidiary within the meaning of Item 601(b)(21)(ii) of Regulation S-K.
March 28, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
March 28, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
March 28, 2012	EX-99.1	Genta Incorporated Reports Fourth Quarter and 2011 Year-End Financial Results Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports Fourth Quarter and 2011 Year-End Financial Results BERKELEY HEIGHTS, NJ – March 28, 2012 – Genta Incorporated (OTCBB: GNTA.OB) today reported results for the quarter and year ended December 31, 2011. For the fourth quarter of 2011, the Company reported a net loss of $(32.1) million, or $(0.04) net loss per basic a
March 28, 2012	EX-99.1	Genta Incorporated Reports Fourth Quarter and 2011 Year-End Financial Results Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports Fourth Quarter and 2011 Year-End Financial Results BERKELEY HEIGHTS, NJ – March 28, 2012 – Genta Incorporated (OTCBB: GNTA.OB) today reported results for the quarter and year ended December 31, 2011. For the fourth quarter of 2011, the Company reported a net loss of $(32.1) million, or $(0.04) net loss per basic a
March 23, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K genta201203238k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 23, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866
March 16, 2012	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 16, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
March 6, 2012	SC 13G	GNTA / / SABBY MANAGEMENT, LLC - SABBY MANAGEMENT, LLC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 15, 2012	EX-10.1	THIRTEENTH AMENDMENT AGREEMENT EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 THIRTEENTH AMENDMENT AGREEMENT This THIRTEENTH AMENDMENT AGREEMENT (this “Agreement”), dated as of February 15, 2012, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set fo
February 15, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 15, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File N
February 14, 2012	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G, dated February 14, 2011, with respect to the shares of Genta Incorporated’s Common Stock, par value $0.
February 14, 2012	SC 13G/A	GNTA / / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 3 Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2012	SC 13G/A	GNTA / / BAKER FELIX - FORM SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2012	SC 13G/A	GNTA / / RA CAPITAL MANAGEMENT, L.P. - SC 13GA Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genta Incorporated (Name of Issuer) Common Shares, $0.001 par value (Title of Class of Securities) 37245M801 (CUSIP Number) February 06, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
February 14, 2012	SC 13G/A	GNTA / / Boxer Capital, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Genta Incorporated (Name of issuer) Common Stock, $0.001 par value (Title of class of securities) 37245M603 (CUSIP number) December 31, 2011 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule
February 10, 2012	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 10, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
January 27, 2012	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 27, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
January 24, 2012	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 23, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File Nu
January 19, 2012	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 19, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
January 19, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 19, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
January 19, 2012	EX-99.1	New Clinical Trial Confirms the Activity of Tesetaxel in Patients with Advanced Gastric Cancer - New Results Confirm Response Rate and Low Incidence of Serious Side Effects Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 New Clinical Trial Confirms the Activity of Tesetaxel in Patients with Advanced Gastric Cancer - New Results Confirm Response Rate and Low Incidence of Serious Side Effects BERKELEY HEIGHTS, NJ – January 19, 2012 - Genta Incorporated (OTCBB: GNTA.OB) today announced results from the Company’s Phase 2b, confirmatory clinical trial of tesetax
January 19, 2012	EX-10.1	TWELFTH AMENDMENT AGREEMENT EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 TWELFTH AMENDMENT AGREEMENT This TWELFTH AMENDMENT AGREEMENT (this “Agreement”), dated as of January 18, 2012, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set forth in
January 13, 2012	8-K	Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 13, 2012 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
December 30, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 30, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
December 23, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 23, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
December 19, 2011	EX-10.1	ELEVENTH AMENDMENT AGREEMENT EX-10.1 2 ex10-1.htm ELEVENTH AMENDMENT AGREEMENT Exhibit 10.1 ELEVENTH AMENDMENT AGREEMENT This ELEVENTH AMENDMENT AGREEMENT (this “Agreement”), dated as of December 16, 2011, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the mea
December 19, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 16, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File N
December 16, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 16, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
December 8, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 8, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
December 8, 2011	EX-99.1	200 Connell Drive Berkeley Heights, NJ 07922 Genta Announces Results from Clinical Trial of Tesetaxel as Initial Chemotherapy for Women with Recurrent Breast Cancer - Results Confirm High Response Rates and Low Incidence of Serious Side Effects Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Announces Results from Clinical Trial of Tesetaxel as Initial Chemotherapy for Women with Recurrent Breast Cancer - Results Confirm High Response Rates and Low Incidence of Serious Side Effects BERKELEY HEIGHTS, NJ – December 8, 2011 - Genta Incorporated (OTCBB: GNTA.OB) today announced presentation of results from the Company’s Phase
December 5, 2011	EX-10.2	EIGHTH AMENDMENT AGREEMENT Exhibit 10.2 EIGHTH AMENDMENT AGREEMENT This EIGHTH AMENDMENT AGREEMENT (this “Agreement”), dated as of November 21, 2011, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement (
December 5, 2011	EX-10.4	TENTH AMENDMENT AGREEMENT EX-10.4 5 ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 TENTH AMENDMENT AGREEMENT This TENTH AMENDMENT AGREEMENT (this “Agreement”), dated as of December 4, 2011, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set forth in the
December 5, 2011	EX-10.1	SEVENTH AMENDMENT AGREEMENT EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SEVENTH AMENDMENT AGREEMENT This SEVENTH AMENDMENT AGREEMENT (this “Agreement”), dated as of November 16, 2011, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set forth in
December 5, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 2, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File Nu
December 5, 2011	EX-10.3	NINTH AMENDMENT AGREEMENT Exhibit 10.3 NINTH AMENDMENT AGREEMENT This NINTH AMENDMENT AGREEMENT (this “Agreement”), dated as of November 28, 2011, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement (as
November 10, 2011	EX-10.10	FIFTH AMENDMENT AGREEMENT Exhibit 10.10 FIFTH AMENDMENT AGREEMENT This FIFTH AMENDMENT AGREEMENT (this “Agreement”), dated as of October 31, 2011, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement (as
November 10, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 10, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
November 10, 2011	EX-10.7	SECOND AMENDMENT AGREEMENT Exhibit 10.7 SECOND AMENDMENT AGREEMENT This SECOND AMENDMENT AGREEMENT (this “Agreement”), dated as of October 12, 2011, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement (a
November 10, 2011	EX-10.6	AMENDMENT AGREEMENT Exhibit 10.6 AMENDMENT AGREEMENT This AMENDMENT AGREEMENT (this “Agreement”), dated as of October 7, 2011, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties whose names are set forth on Exhibit A attached hereto (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set forth
November 10, 2011	EX-10.8	THIRD AMENDMENT AGREEMENT Exhibit 10.8 THIRD AMENDMENT AGREEMENT This THIRD AMENDMENT AGREEMENT (this “Agreement”), dated as of October 19, 2011, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement (as
November 10, 2011	EX-10.11	SIXTH AMENDMENT AGREEMENT Exhibit 10.11 SIXTH AMENDMENT AGREEMENT This SIXTH AMENDMENT AGREEMENT (this “Agreement”), dated as of November 7, 2011, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement (as
November 10, 2011	EX-10.9	FOURTH AMENDMENT AGREEMENT Exhibit 10.9 FOURTH AMENDMENT AGREEMENT This FOURTH AMENDMENT AGREEMENT (this “Agreement”), dated as of October 24, 2011, is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties (each a “Holder” and collectively the “Holders”). Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase Agreement (a
November 10, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 [ ] TRANSITION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19635 GE
November 10, 2011	EX-99.1	200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports Third Quarter 2011 Financial Results and Recent Corporate Highlights -- Tesetaxel Clinical Data Pending Multiple Presentations -- Response and progression-free survival in 1st-li 200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports Third Quarter 2011 Financial Results and Recent Corporate Highlights - Tesetaxel Clinical Data Pending Multiple Presentations - Response and progression-free survival in 1st-line breast cancer expected at 2011 San Antonio Breast Cancer Symposium in December - Overall survival and response in 2nd-line gastric cancer expected at 2012 ASCO GI Symposium in January BERKELEY HEIGHTS, NJ ? November 10, 2011 ? Genta Incorporated (OTCBB: GNTA.
October 25, 2011	SC 13G	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(B), (C), AND (D) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2 (Amendment No. ______)* Ge SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(B), (C), AND (D) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2 (Amendment No.
October 25, 2011	SC 13G	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(B), (C), AND (D) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2 (Amendment No. ______)* Ge SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13D-1(B), (C), AND (D) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2 (Amendment No.
October 21, 2011	8-K	Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 21, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
October 7, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 7, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File N
October 6, 2011	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.__)* Genta Incorporated (Name of Issuer) Common Shares, $0.001 par value (Title of Class of Securities) (CUSI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Genta Incorporated (Name of Issuer) Common Shares, $0.001 par value (Title of Class of Securities) 37245M801 (CUSIP Number) September 9, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
September 23, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 23, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission Fil
September 23, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for use of the Commissiononly only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy S
September 16, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 16, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission Fil
September 12, 2011	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for use of the Commissiononly only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy S
September 9, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 9, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
September 6, 2011	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 2, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File N
September 6, 2011	EX-4.2	GENTA INCORPORATED Form of Senior Secured Cash Collateralized Convertible Promissory Note due September 9, 2021 Exhibit 4.2 THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND SUCH STATE SECURITIES LAWS. GENTA IN
September 6, 2011	EX-4.1	GENTA INCORPORATED Form of Senior Secured Convertible Promissory Note due September 9, 2021 G Note No. _____ $___________ Exhibit 4.1 THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED, OR OTHERWISE DISPOSED OF IN THE ABSENCE OF SUCH REGISTRATION OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND SUCH STATE SECURITIES LAWS. GENTA IN
September 6, 2011	EX-10.2	NOTE CONVERSION AND AMENDMENT AGREEMENT Exhibit 10.2 NOTE CONVERSION AND AMENDMENT AGREEMENT This NOTE CONVERSION AND AMENDMENT AGREEMENT (this “Agreement”), as of September 2, 2011 (the “Amendment Date”), is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties whose names are set forth on Exhibit A attached hereto (each a “Holder” and collectively the “Holders”). WHEREAS, the Company
September 6, 2011	EX-4.5	GENTA INCORPORATED FORM SENIOR SECURED CONVERTIBLE PROMISSORY NOTE PURCHASE WARRANT Note Warrant No. [______] Issue Date: September 9, 2011 Exhibit 4.5 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. GENTA INCORPORA
September 6, 2011	EX-4.4	GENTA INCORPORATED FORM SENIOR SECURED CONVERTIBLE PROMISSORY NOTE PURCHASE WARRANT Note Warrant No. [______] Issue Date: September 9, 2011 Exhibit 4.4 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. GENTA INCORPORA
September 6, 2011	EX-4.3	FORM OF COMMON STOCK PURCHASE WARRANT GENTA INCORPORATED Warrant Shares: [___________] Issue Date: September 9, 2011 Exhibit 4.3 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. FORM OF COMMON
September 6, 2011	EX-10.1	SECURITIES PURCHASE Dated as of September 2, 2011 by and among GENTA INCORPORATED SECURITIES PURCHASE AGREEMENT Exhibit 10.1 SECURITIES PURCHASE AGREEMENT Dated as of September 2, 2011 by and among GENTA INCORPORATED and THE PURCHASERS LISTED ON EXHIBIT A SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) dated as of September 2, 2011 (the “Effective Date”) by and among Genta Incorporated, a Delaware corporation (the “Company”), and each of the purchasers of the senior secur
September 6, 2011	EX-10.3	GENERAL SECURITY AGREEMENT Dated as of September 2, 2011 THE GRANTORS REFERRED TO HEREIN as Grantors TANG CAPITAL PARTNERS, L.P. as Agent GENERAL SECURITY AGREEMENT Exhibit 10.3 GENERAL SECURITY AGREEMENT Dated as of September 2, 2011 between THE GRANTORS REFERRED TO HEREIN as Grantors and TANG CAPITAL PARTNERS, L.P. as Agent GENERAL SECURITY AGREEMENT This General Security Agreement dated as of September 2, 2011 (the “Agreement”) between Genta Incorporated, a Delaware corporation (the “Company”), the other Persons listed on the signature pages hereof as Gran
September 6, 2011	EX-10.4	SECURITY AGREEMENT Exhibit 10.4 SECURITY AGREEMENT This Security Agreement dated as of September 2, 2011 (the “Agreement”) between Genta Incorporated, a Delaware corporation (the “Grantor”) and Tang Capital Partners, L.P., as agent (together with any successor agent, the “Agent”) for the Purchasers (as defined in the Securities Purchase Agreement (as defined below)). Terms used herein and not otherwise defined herei
September 6, 2011	EX-10.5	July 25, 2011 Exhibit 10.5 July 25, 2011 STRICTLY CONFIDENTIAL Raymond P. Warrell Jr., M.D. Chairman of the Board and Chief Executive Officer Genta Incorporated 200 Connell Drive Berkeley Heights, NJ 07922 Dear Dr. Warrell: This letter (the “Agreement”) constitutes the agreement between Genta Incorporated (the “Company”) and Rodman & Renshaw, LLC (“Rodman”) that Rodman shall serve as the exclusive placement age
September 6, 2011	EX-99.1	Genta Completes Financing of up to $12.7 Million -- Proceeds expected to enable initiation of global registration studies for tesetaxel -- Accelerated development of pipeline products anticipated 200 Connell Drive Berkeley Heights, NJ 07922 Genta Completes Financing of up to $12.
August 11, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 [ ] TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19635 GENTA I
August 11, 2011	EX-99.1	Genta Incorporated Reports Second Quarter 2011 Financial Results and Recent Corporate Highlights Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports Second Quarter 2011 Financial Results and Recent Corporate Highlights BERKELEY HEIGHTS, NJ – August 11, 2011 – Genta Incorporated (OTCBB: GNTA.OB) today reported results for the quarter and six months ended June 30, 2011. Tesetaxel, the leading oral taxane in clinical development, is the Company’s primary research
August 11, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 11, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File N
July 29, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 29, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
July 8, 2011	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 8, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
July 8, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 8, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
June 29, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 29, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
June 29, 2011	EX-99.1	Genta Updates Tesetaxel Clinical Trials Progress at the BIO International Business Forum Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Updates Tesetaxel Clinical Trials Progress at the BIO International Business Forum BERKELEY HEIGHTS, NJ – June 29, 2011– Genta Incorporated (OTC: GNTA.OB) provided a comprehensive update of its clinical trials programs with tesetaxel, the Company’s lead investigational drug. The information was presented by Genta’s Chairman and Chief
June 24, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 24, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
June 10, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 10, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
June 8, 2011	EX-99.1	Tesetaxel Results from Multiple Dose-Ranging Clinical Trials Updated at ASCO -- Safety of weekly dosing schedule provides “dose-dense” option -- Low incidence of neuropathy despite extended therapy -- Published and ongoing combination trials with cap Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Tesetaxel Results from Multiple Dose-Ranging Clinical Trials Updated at ASCO - Safety of weekly dosing schedule provides “dose-dense” option - Low incidence of neuropathy despite extended therapy - Published and ongoing combination trials with capecitabine (Xeloda®) BERKELEY HEIGHTS, NJ – June 8, 2011 – Genta Incorporated (OTCBB: GNTA) anno
June 8, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 8, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
June 3, 2011	EX-99.1	Genta Presents Updated Results of Phase 2 Trial of Tesetaxel in Patients with Advanced Gastric Cancer --Weight-based dose established for global clinical studies Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Presents Updated Results of Phase 2 Trial of Tesetaxel in Patients with Advanced Gastric Cancer -Weight-based dose established for global clinical studies BERKELEY HEIGHTS, NJ – June 3, 2011 – Genta Incorporated (GNTA.OB) today announced updated interim results from a trial of tesetaxel used as 2nd-line treatment in patients with adva
June 3, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 3, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
June 2, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 2, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
June 2, 2011	EX-99.1	Tesetaxel Results as Initial Chemotherapy for Women with Breast Cancer Presented at ASCO - Early Data Show High Response Rate, Low Incidence of Neuropathy and Hair Loss Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Tesetaxel Results as Initial Chemotherapy for Women with Breast Cancer Presented at ASCO - Early Data Show High Response Rate, Low Incidence of Neuropathy and Hair Loss BERKELEY HEIGHTS, NJ – June 2, 2011 - Genta Incorporated (OTCBB: GNTA) today announced interim results that show a high objective response rate in an ongoing trial using tes
May 27, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 27, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 23, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 23, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 23, 2011	EX-99.1	Phase 3 Trial of Genasense® in Advanced Melanoma Does Not Show Significant Increase in Overall Survival Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Phase 3 Trial of Genasense? in Advanced Melanoma Does Not Show Significant Increase in Overall Survival BERKELEY HEIGHTS, NJ ? May 23, 2011 - Genta Incorporated (OTCBB: GNTA) today announced that overall survival for patients treated with Genasense? (oblimersen sodium) Injection plus chemotherapy in AGENDA, the Company?s Phase 3 trial of Ge
May 20, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 20, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 17, 2011	EX-99.1	Genta Announces Clinical Presentations on Lead Compounds, Tesetaxel and Genasense®, at 2011 Annual ASCO Meeting Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Announces Clinical Presentations on Lead Compounds, Tesetaxel and Genasense®, at 2011 Annual ASCO Meeting BERKELEY HEIGHTS, NJ – May 17, 2011 – Genta Incorporated (OTC: GNTA.OB) today announced that data from clinical trials of the Company's late-stage compounds, Genasense® (oblimersen sodium) Injection and tesetaxel, will be presente
May 17, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for use of the Commissiononly (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement
May 17, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 17, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 16, 2011	EX-99.1	Genta Incorporated Reports First Quarter 2011 Corporate Highlights and Financial Results 200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports First Quarter 2011 Corporate Highlights and Financial Results [webcast] BERKELEY HEIGHTS, NJ – May 16, 2011 – Genta Incorporated (OTC: GNTA.
May 16, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 [ ] TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19635 GENTA
May 16, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 6, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 6, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numbe
May 3, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 3, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numbe
May 3, 2011	EX-99.1	Genta Initiates Front-Line Combination Trial of Tesetaxel in Patients with Advanced Gastric Cancer --Trial Opening in Seoul, Korea Adds Tesetaxel to Global Standard of Care -- Program Seeks to Improve Patient Outcomes and Reduce Side Effects Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Initiates Front-Line Combination Trial of Tesetaxel in Patients with Advanced Gastric Cancer -Trial Opening in Seoul, Korea Adds Tesetaxel to Global Standard of Care - Program Seeks to Improve Patient Outcomes and Reduce Side Effects BERKELEY HEIGHTS, NJ ? May 3, 2011 ? Genta Incorporated (GNTA.OB) today announced that the Company has
April 29, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 29, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
April 26, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 26, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
April 26, 2011	EX-99.1	Genta Initiates Tesetaxel Clinical Trial in Japan to Kickoff Comprehensive Development Program in East Asia --Trial is First Global Step in Targeting Patients with Advanced Gastric Cancer Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Initiates Tesetaxel Clinical Trial in Japan to Kickoff Comprehensive Development Program in East Asia -Trial is First Global Step in Targeting Patients with Advanced Gastric Cancer BERKELEY HEIGHTS, NJ – April 26, 2011 – Genta Incorporated (GNTA.OB) today announced that the Company has initiated a new clinical trial of tesetaxel in Ja
April 21, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 21, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
April 21, 2011	EX-99.1	200 Connell Drive Berkeley Heights, NJ 07922 Genta Updates Guidance on Survival Results from Phase 3 AGENDA Trial of Genasense® in Advanced Melanoma -- Final Top-Line Survival Results Expected in May 2011 -- AGENDA Abstract Accepted for Presentation Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Updates Guidance on Survival Results from Phase 3 AGENDA Trial of Genasense? in Advanced Melanoma - Final Top-Line Survival Results Expected in May 2011 - AGENDA Abstract Accepted for Presentation at ASCO BERKELEY HEIGHTS, NJ ? April 21, 2011 ? Genta Incorporated (GNTA.OB) today updated its formal guidance for release of results from
April 15, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 15, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
April 8, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 8, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
March 30, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 30, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
March 30, 2011	EX-10.10	GENTA INCORPORATED 200 Connell Drive Berkeley Heights, NJ 07922 Exhibit 10.10 EXECUTION COPY GENTA INCORPORATED 200 Connell Drive Berkeley Heights, NJ 07922 Amended and Restated January 20, 2011 Dr. Raymond P. Warrell, Jr. 200 Connell Drive Berkeley Heights, NJ 07922 Dear Dr. Warrell: We are pleased that you are willing to continue to serve as Chief Executive Officer, and Chairman of the Board of Directors (the “Board”), of Genta Incorporated, a Delaware corpo
March 30, 2011	EX-3.1.B	EX-3.1.B Exhibit 3.1.b
March 30, 2011	EX-21	GENTA INCORPORATED SUBSIDIARIES OF THE REGISTRANT EX-21 8 ex21.htm EXHIBIT 21 Exhibit 21 GENTA INCORPORATED SUBSIDIARIES OF THE REGISTRANT The names of the Company’s subsidiaries are omitted. Such subsidiaries would not, if considered in the aggregate as a single subsidiary, constitute a significant subsidiary within the meaning of Item 601(b)(21)(ii) of Regulation S-K.
March 30, 2011	EX-3.1.C	EX-3.1.C Exhibit 3.1.c
March 30, 2011	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2010 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 000-19635 GENTA INCORPORATED (Exact
March 30, 2011	EX-3.1.R	EX-3.1.R Exhibit 3.1.r
March 30, 2011	EX-99.1	200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports Fourth Quarter and 2010 Year-End Financial Results and Updates Key Product and Corporate Developments -- Genasense®: Survival data from Phase 3 melanoma trial due April 2011 -- T Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports Fourth Quarter and 2010 Year-End Financial Results and Updates Key Product and Corporate Developments - Genasense?: Survival data from Phase 3 melanoma trial due April 2011 - Tesetaxel: Multiple clinical trial presentations expected at ASCO - Oral-Gallium Compounds: Eight candidate agents complete initial animal s
March 30, 2011	EX-3.1.D	EX-3.1.D Exhibit 3.1.d
March 30, 2011	EX-3.1.U	EX-3.1.U Exhibit 3.1.u
March 25, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 25, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
March 18, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 18, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
March 11, 2011	8-K	Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 11, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File Numb
March 4, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 4, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
February 17, 2011	EX-99.1	Board of Directors of Genta Incorporated Announce Reverse Split of Company’s Common Stock Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Board of Directors of Genta Incorporated Announce Reverse Split of Company?s Common Stock BERKELEY HEIGHTS, NJ ? February 17, 2011 ? Genta Incorporated (OTCBB: GNTA) announced today that its Board of Directors has approved a one-for-fifty reverse stock split of Genta?s common stock. The split will be effective with the open of trading on Fr
February 17, 2011	EX-3.1	CERTIFICATE OF AMENDMENT RESTATED CERTIFICATE OF INCORPORATION GENTA INCORPORATED Pursuant to Section 242 of the General Corporation Law of the State of Delaware Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF GENTA INCORPORATED Pursuant to Section 242 of the General Corporation Law of the State of Delaware Genta Incorporated (the “Corporation”), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. The Restated Certificate o
February 17, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 17, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File N
February 14, 2011	EX-99.1	JOINT FILING AGREEMENT Exhibit 1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G, dated February 14, 2011, with respect to the shares of Genta Incorporated’s Common Stock, par value $0.
February 14, 2011	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2 (Amendment No. 2)* Genta SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13D-2 (Amendment No.
February 14, 2011	SC 13G/A	SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 2)* GENTA INCORPORATED (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) (CUSIP Numbe SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2011	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genta Incorporated (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) (CUSIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Genta Incorporated (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37245M603 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
February 11, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 11, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
February 10, 2011	EX-99.1	Genta Initiates Trial with Tesetaxel as First- and Second-Line Chemotherapy for Patients with Advanced Prostate Cancer Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Initiates Trial with Tesetaxel as First- and Second-Line Chemotherapy for Patients with Advanced Prostate Cancer BERKELEY HEIGHTS, NJ – February 10, 2011 – Genta Incorporated (GNTA.OB) today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced prostate cancer. Tesetaxel, the lead
February 10, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 10, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
January 28, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 28, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
January 21, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 21, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
January 20, 2011	EX-99.1	Genta Appoints Ana I. Stancic and Dr. Marvin E. Jaffe to Board of Directors Douglas G. Watson to Retire as Director Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Appoints Ana I. Stancic and Dr. Marvin E. Jaffe to Board of Directors Douglas G. Watson to Retire as Director BERKELEY HEIGHTS, NJ – January 20, 2011 – Genta Incorporated (GNTA.OB) announced today the appointments of Ana I. Stancic and Dr. Marvin E. Jaffe, MD, as members of the Company’s Board of Directors. The Company also announced
January 20, 2011	EX-17.1	EX-17.1 Exhibit 17.1
January 20, 2011	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 16, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
January 18, 2011	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number:3235-0145 Expires: February 28, 2009 Estimated average burden hours per response? 10.4 AMENDMENT NO. 1. TO SCHEDULE 13G Under the Securities Exchange Act of 1934 Genta Incorporated (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37245M504 (CUSIP Number) December 31, 2010 (
January 14, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 14, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
January 14, 2011	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Genta Incorporated (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securi UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Genta Incorporated (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 37245M702 (CUSIP Number) Raymond P. Warrell, Jr., M.D. Chairman and Chief Executive Officer Genta Incorporated 200 Connell Drive Berkeley Height
January 11, 2011	EX-99.1	Genta Provides Comprehensive Update of Research and Development Activities -- Genasense® Phase 3 survival result in melanoma due early Q2 2011 -- Multiple presentations from tesetaxel clinical trials expected at ASCO -- Lead oral-gallium candidates a EXHIBIT 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Provides Comprehensive Update of Research and Development Activities - Genasense? Phase 3 survival result in melanoma due early Q2 2011 - Multiple presentations from tesetaxel clinical trials expected at ASCO - Lead oral-gallium candidates advance to animal studies BERKELEY HEIGHTS, NJ ? January 11, 2011 ? Genta Incorporated (OTCBB: G
January 11, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 11, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
January 7, 2011	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 7, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File N
January 3, 2011	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 29, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
January 3, 2011	8-K	Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 1, 2011 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File Num
December 29, 2010	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 29, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
December 15, 2010	EX-4.1	FORM OF COMMON STOCK PURCHASE WARRANT GENTA INCORPORATED Warrant Shares: [___________] Issue Date: [__], 2010 Exhibit 4.1 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. FORM OF COMMON
December 15, 2010	EX-99.1	200 Connell Drive Berkeley Heights, NJ 07922 Genta Completes $5 Million Financing -- Proceeds Enable Survival Determination from Phase 3 AGENDA Trial -- Accelerates Tesetaxel Clinical Development Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Completes $5 Million Financing - Proceeds Enable Survival Determination from Phase 3 AGENDA Trial - Accelerates Tesetaxel Clinical Development BERKELEY HEIGHTS, NJ ? December 15, 2010 ? Genta Incorporated (OTCBB: GNTA) announced today that the Company has entered into definitive agreements with institutional investors that released $5
December 15, 2010	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 14, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File N
December 15, 2010	EX-10.2	AMENDMENT AGREEMENT EX-10.2 4 ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 AMENDMENT AGREEMENT This Amendment Agreement (this “Agreement”), effective as of December 14, 2010, (the “Effective Date”), is made by and among Genta Incorporated, a Delaware corporation (the “Company”), and the holders of June 2008 Notes (as defined below) set forth on the signature pages hereto (each a “Holder” and collectively the “Holders”). WHER
December 15, 2010	EX-10.1	AMENDMENT AND CONSENT AGREEMENT Exhibit 10.1 AMENDMENT AND CONSENT AGREEMENT This Amendment and Consent Agreement (this “Agreement”), dated as of December 14, 2010, and effective as of the Effective Date (as defined below), is made by and among Genta Incorporated, a Delaware corporation (the “Company”), and the undersigned parties whose names are set forth on Exhibit A attached hereto (each a “Holder” and collectively the “Holde
November 19, 2010	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the app UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
November 12, 2010	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 11, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
November 12, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 o TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19635 GENTA
November 12, 2010	EX-10.1	GENTA INCORPORATED 2009 STOCK INCENTIVE PLAN (As Amended and Restated April 1, 2010) TABLE OF CONTENTS Page ARTICLE I GENERAL 1 1.1 Purpose 1 1.2 Administration 1 1.3 Persons Eligible for Awards 2 1.4 Types of Awards Under Plan 2 1.5 Shares Available Exhibit 10.1 GENTA INCORPORATED 2009 STOCK INCENTIVE PLAN (As Amended and Restated April 1, 2010) TABLE OF CONTENTS Page ARTICLE I GENERAL 1 1.1 Purpose 1 1.2 Administration 1 1.3 Persons Eligible for Awards 2 1.4 Types of Awards Under Plan 2 1.5 Shares Available for Awards 2 1.6 Definitions of Certain Terms 3 ARTICLE II AWARDS UNDER THE PLAN 5 2.1 Agreements Evidencing Awards 5 2.2 No Rights as a
November 12, 2010	EX-99.1	Genta Incorporated Reports Third Quarter 2010 Corporate Highlights and Financial Results EXHIBIT 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports Third Quarter 2010 Corporate Highlights and Financial Results [webcast] BERKELEY HEIGHTS, NJ – November 11, 2010 – Genta Incorporated (OTCBB: GNTA.OB) today announced financial results for the quarter ending September 30, 2010. Recent corporate highlights include: · Survival results from AGENDA Phase 3 trial of Ge
November 8, 2010	EX-10.1	AMENDMENT AND ACKNOWLEDGMENT AGREEMENT Exhibit 10.1 AMENDMENT AND ACKNOWLEDGMENT AGREEMENT This Amendment And Acknowledgment Agreement (this “Agreement”), dated as of November 5, 2010, and effective as of the Effective Date (as defined below), is made by and among Genta Incorporated, a Delaware corporation (the “Company”), and the undersigned parties whose names are set forth on Exhibit A attached hereto (each a “Holder” and collective
November 8, 2010	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 5, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
November 8, 2010	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 8, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
November 8, 2010	EX-99.1	Genta Initiates Trial with Tesetaxel as First-Line Chemotherapy for Women with Metastatic Breast Cancer Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Initiates Trial with Tesetaxel as First-Line Chemotherapy for Women with Metastatic Breast Cancer BERKELEY HEIGHTS, NJ – November 8, 2010 – Genta Incorporated (OTCBB: GNTA.OB) today announced that the Company has initiated a new Phase 2b clinical trial of tesetaxel as 1st-line chemotherapy for women with metastatic breast cancer. Tese
November 5, 2010	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the app UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State
November 2, 2010	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 2, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
November 2, 2010	EX-99.1	200 Connell Drive Berkeley Heights, NJ 07922 Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Awarded Two Federal Grants Totaling $488,958 for Qualifying Therapeutic Discovery Projects BERKELEY HEIGHTS, NJ – November 2, 2010 – Genta Incorporated (OTCBB: GNTA.OB) today announced that the Company has been awarded cash grants totaling approximately $488,958 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTD
November 1, 2010	EX-99	Genta Receives Scientific Advice from European Medicines Agency Supporting Randomized Phase 3 Trial of Tesetaxel in Patients with Advanced Gastric Cancer Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Receives Scientific Advice from European Medicines Agency Supporting Randomized Phase 3 Trial of Tesetaxel in Patients with Advanced Gastric Cancer BERKELEY HEIGHTS, NJ ? November 1, 2010 ? Genta Incorporated (OTCBB: GNTA.OB) today announced that the Company has received Scientific Advice from the European Medicines Agency (EMA) on th
November 1, 2010	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 1, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
October 22, 2010	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 22, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
October 18, 2010	EX-99.1	Stock Symbol for Genta Incorporated to Revert to GNTA.OB Change Effective Monday October 18, 2010 EXHIBIT 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Stock Symbol for Genta Incorporated to Revert to GNTA.OB Change Effective Monday October 18, 2010 BERKELEY HEIGHTS, NJ – October 15, 2010 – Genta Incorporated (OTCBB: GETA.OB) today announced that the Financial Industry Regulatory Authority (FINRA) has granted the Company’s request that the trading symbol for the Company’s common stock reve
October 18, 2010	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 15, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
October 18, 2010	EX-99.2	Stock Symbol for Genta Incorporated Reverts to GNTA.OB Change Effective Monday October 18, 2010 EXHIBIT 99.2 200 Connell Drive Berkeley Heights, NJ 07922 Stock Symbol for Genta Incorporated Reverts to GNTA.OB Change Effective Monday October 18, 2010 (Re-Release) BERKELEY HEIGHTS, NJ – October 18, 2010 – Genta Incorporated (OTCBB: GNTA.OB) today announced that the Financial Industry Regulatory Authority (FINRA) has granted the Company’s request that the trading symbol for the Company’s common
October 12, 2010	EX-99.1	Tesetaxel Granted Orphan Drug Designation for Gastric Cancer by European Medicines Agency Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Tesetaxel Granted Orphan Drug Designation for Gastric Cancer by European Medicines Agency BERKELEY HEIGHTS, NJ – October 11, 2010 – Genta Incorporated (OTCBB: GETA.OB) today announced that tesetaxel, the leading oral taxane in clinical development, has been designated as an Orphan Drug by the European Medicines Agency for gastric cancer. Th
October 12, 2010	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 11, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File
October 8, 2010	8-K	Material Modification to Rights of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 8, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File Num
October 8, 2010	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2010 GENTA INCORPORATED (Exact name of registrant specified in its charter) Delaware 0-19635 33-0326866 (State or other jurisdiction of incorporation) (Commission File Numb
September 24, 2010	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 24, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission Fil
September 24, 2010	EX-99.1	200 Connell Drive Berkeley Heights, NJ 07922 Genta Initiates New Trial of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Bladder Cancer Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Initiates New Trial of Tesetaxel, the Leading Clinical-Stage Oral Taxane, in Patients with Advanced Bladder Cancer BERKELEY HEIGHTS, NJ ? September 24, 2010 ? Genta Incorporated (OTCBB: GETA.OB) today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel
September 24, 2010	RW	200 Connell Drive 200 Connell Drive Berkeley Heights, NJ 07922 September 24, 2010 VIA EDGAR AND FEDERAL EXPRESS Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Genta Incorporated Request to Withdraw Registration Statement on Form S-1 File No.
August 19, 2010	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 16, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File N
August 19, 2010	EX-16.1	EX-16.1 Exhibit 16.1
August 12, 2010	EX-99.1	Genta Incorporated Reports Second Quarter 2010 Corporate Highlights and Financial Results Exhibit 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports Second Quarter 2010 Corporate Highlights and Financial Results BERKELEY HEIGHTS, NJ – August 12, 2010 – Genta Incorporated (OTCBB: GETAD.OB) today announced financial results for the quarter ending June 30, 2010. Corporate highlights for the quarter included: · Tesetaxel dose-ranging studies show potential activit
August 12, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 [ ] TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19635 GENTA I
August 12, 2010	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 12, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File N
July 30, 2010	EX-3.1	CERTIFICATE OF AMENDMENT RESTATED CERTIFICATE OF INCORPORATION GENTA INCORPORATED Pursuant to Section 242 of the General Corporation Law of the State of Delaware EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF GENTA INCORPORATED Pursuant to Section 242 of the General Corporation Law of the State of Delaware Genta Incorporated (the “Corporation”), a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. The Restated Certificate o
July 30, 2010	EX-99.1	Board of Directors of Genta Incorporated Announce Reverse Split of Company’s Common Stock EXHIBIT 99.1 200 Connell Drive Berkeley Heights, NJ 07922 Board of Directors of Genta Incorporated Announce Reverse Split of Company’s Common Stock BERKELEY HEIGHTS, NJ – July 30, 2010 – Genta Incorporated (OTCBB: GETA) announced today that its Board of Directors has approved a one-for-one hundred reverse stock split of Genta’s common stock, and that the split will be effective with the open of tr
July 30, 2010	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 30, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
July 19, 2010	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number:3235-0145 Expires: February 28, 2009 Estimated average burden hours per response? 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 Genta Incorporated (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 37245M504 (CUSIP Number) July 19, 2010 (Date of Event which Requ
July 19, 2010	EX-1	JOINT FILING AGREEMENT EX-1 2 gentasch13gex1.htm Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of July 19, 2010, is entered into by and among BAM Management, LLC, a Delaware limited liability company, AM Investment Partners, LLC, a Delaware limited liability company,, BAM Opportunity Fund SPV, LLC, a Delaware limited liability company, Ross Berman, an individual, Hal Mintz, an individual , Adam
June 15, 2010	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
June 7, 2010	EX-99.1	Pooled Results of Early Endpoints from Phase 3 Trials of Genasense® in Advanced Melanoma Presented at ASCO 200 Connell Drive Berkeley Heights, NJ 07922 Pooled Results of Early Endpoints from Phase 3 Trials of Genasense? in Advanced Melanoma Presented at ASCO BERKELEY HEIGHTS, NJ ? June 6, 2010 ? Genta Incorporated (OTCBB: GETA.
June 7, 2010	EX-99.2	Tesetaxel Results from Two Clinical Dose-Ranging Trials Presented at ASCO — Weekly Dosing Schedule Offers Opportunity for “Dose-Dense” Chemotherapy — Low Incidence of Neuropathy with Extended Therapy —Potential Activity in Patients with Taxane-Resist 200 Connell Drive Berkeley Heights, NJ 07922 Tesetaxel Results from Two Clinical Dose-Ranging Trials Presented at ASCO ? Weekly Dosing Schedule Offers Opportunity for ?Dose-Dense? Chemotherapy ? Low Incidence of Neuropathy with Extended Therapy ?Potential Activity in Patients with Taxane-Resistant Breast Cancer BERKELEY HEIGHTS, NJ ? June 7, 2010 ? Genta Incorporated (OTCBB: GETA.
June 7, 2010	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 6, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 13, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 ¨ TRANSITION REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19635 GENTA INCO
May 13, 2010	EX-99.1	Genta Incorporated Announces First Quarter 2010 Financial Results 200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Announces First Quarter 2010 Financial Results BERKELEY HEIGHTS, NJ – May 13, 2010 – Genta Incorporated (OTCBB: GETA.
May 13, 2010	EX-10.4	EX-10.4
May 13, 2010	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 13, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Numb
May 7, 2010	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 4, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction of Incorporation) (Commission File Number)
April 27, 2010	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: o Preliminary Proxy Statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
April 20, 2010	EX-10.1	AMENDED AND RESTATED NOTE CONVERSION AND AMENDMENT AGREEMENT AMENDED AND RESTATED NOTE CONVERSION AND AMENDMENT AGREEMENT This AMENDED AND RESTATED NOTE CONVERSION AND AMENDMENT AGREEMENT (this “Agreement”), effective as of the Effective Date (as defined below), is made by and among GENTA INCORPORATED, a Delaware corporation (the “Company”), and the undersigned parties whose names are set forth on Exhibit A attached hereto (each a “Holder” and collectively the “Holders”).
April 20, 2010	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 20, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
April 20, 2010	EX-99.1	Genta Presents Initial Clinical Data on Use of Gallium Compounds as Treatment for Serious Infections -- AACR presentation suggests potential applications in cystic fibrosis, cancer, and sepsis -- Clinical study in cystic fibrosis to start in May 2010 200 Connell Drive Berkeley Heights, NJ 07922 Genta Presents Initial Clinical Data on Use of Gallium Compounds as Treatment for Serious Infections - AACR presentation suggests potential applications in cystic fibrosis, cancer, and sepsis - Clinical study in cystic fibrosis to start in May 2010 BERKELEY HEIGHTS, NJ – April 20, 2010 – Genta Incorporated (OTCBB: GETA.
April 20, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 19, 2010 GENTA INCORPORATED UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 19, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Charter) Delaware 000-19635 33-0326866 (State or Other Jurisdiction (Commission File Number) (I.R.S. Employ
April 8, 2010	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 5, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
April 6, 2010	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
April 6, 2010	EX-99.1	200 Connell Drive 200 Connell Drive Berkeley Heights, NJ 07922 Genta’s Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer BERKELEY HEIGHTS, NJ – April 6, 2010 – Genta Incorporated (OTCBB: GETA.
April 6, 2010	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 6, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Num
March 31, 2010	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 31, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
March 31, 2010	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 31, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
March 31, 2010	EX-99.1	Genta Initiates Confirmatory Phase 2b Trial of Tesetaxel in Gastric Cancer Genta Initiates Confirmatory Phase 2b Trial of Tesetaxel in Gastric Cancer BERKELEY HEIGHTS, NJ ? March 31, 2010 ? Genta Incorporated (OTCBB: GETA.
March 31, 2010	EX-99.1	Genta Initiates Confirmatory Phase 2b Trial of Tesetaxel in Gastric Cancer Genta Initiates Confirmatory Phase 2b Trial of Tesetaxel in Gastric Cancer BERKELEY HEIGHTS, NJ – March 31, 2010 – Genta Incorporated (OTCBB: GETA.
March 29, 2010	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K For the fiscal year ended December 31, 2009 For the Transition period from to Commission File Number 000-19635 GENTA INCORPORATED (908) 286-9800 Genta Incorporated Tabl UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to SECTION 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2009 o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition period from to Commission File Number 000-19635 GENTA INCORPORATED (Exact nam
March 29, 2010	EX-10.2(B)	AMENDMENT NO. 5 TO LEASE EX-10.2(B) 5 v178509ex10-2b.htm Exhibit 10.2B AMENDMENT NO. 5 TO LEASE This Amendment No. 5 to Lease (this “Amendment No. 5 to Lease”), dated as of September 23, 2009, is made between THE CONNELL COMPANY, a New Jersey corporation (“Landlord”), and GENTA INCORPORATED, a Delaware corporation (“Tenant”). WHEREAS, Landlord and Tenant entered into the Lease dated as of June 28, 2000, which was amended
March 29, 2010	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 29, 2010 GENTA INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19635 33-0326866 (Commission File Nu
March 29, 2010	EX-99.1	Genta Incorporated Reports Fourth Quarter and 2009 Year-End Financial Results 200 Connell Drive Berkeley Heights, NJ 07922 Genta Incorporated Reports Fourth Quarter and 2009 Year-End Financial Results BERKELEY HEIGHTS, NJ – March 29, 2010 – Genta Incorporated (OTCBB: GETA.
March 29, 2010	EX-21	GENTA INCORPORATED SUBSIDIARIES OF THE REGISTRANT EX-21 6 v178509ex21.htm Exhibit 21 GENTA INCORPORATED SUBSIDIARIES OF THE REGISTRANT The names of the Company’s subsidiaries are omitted. Such subsidiaries would not, if considered in the aggregate as a single subsidiary, constitute a significant subsidiary within the meaning of Item 601(b)(21)(ii) of Regulation S-K.

GNTA / Genenta Science S.p.A. - Depositary Receipt (Common Stock) - Depositi SEC, Relazione annuale, dichiarazione di delega

Statistiche di base

SEC Filings

SEC Filings (Chronological Order)

Other Listings